Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience

Steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ruxolitinib (RUX), an oral JAK1 and JAK2 inhibitor, has recently been approved for patients with SR-aGVHD. The aim of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Spałek, Adrianna, Wieczorkiewicz-Kabut, Agata, Koclęga, Anna, Woźniczka, Krzysztof, Węglarz, Patryk, Boral, Kinga, Kata, Dariusz, Zielińska, Patrycja, Helbig, Grzegorz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668796/
https://www.ncbi.nlm.nih.gov/pubmed/35972605
http://dx.doi.org/10.1007/s12185-022-03434-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668796/
https://www.ncbi.nlm.nih.gov/pubmed/35972605
http://dx.doi.org/10.1007/s12185-022-03434-5

Ejemplares similares